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Liver microcirculation plays an essential role in the progression and aggravation of 
chronic liver disease. Hepatic sinusoid environment, mainly composed by hepatocytes, 
liver sinusoidal endothelial cells, Kupffer cells, and hepatic stellate cells, intimately coop-
erate to maintain global liver function and specific phenotype of each cell type. However, 
continuous liver injury significantly deregulates liver cells protective phenotype, leading 
to parenchymal and non-parenchymal dysfunction. Recent data have enlightened the 
molecular processes that mediate hepatic microcirculatory injury, and consequently, 
opened the possibility to develop new therapeutic strategies to ameliorate liver circula-
tion and viability. The present review summarizes the main cellular components of the 
hepatic sinusoid, to afterward focus on non-parenchymal cells phenotype deregulation 
due to chronic injury, in the specific clinical context of liver cirrhosis and derived portal 
hypertension. Finally, we herein detail new therapies developed at the bench-side with 
high potential to be translated to the bedside.
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iNTRODUCTiON—CHRONiC LiveR DiSeASe (CLD)
Chronic liver disease is one of the most important causes of death worldwide representing 1.03 
million deaths per year (1). A variety of toxicants may induce the initiation and progression of 
CLD, being excessive alcohol consumption, viral hepatitis infection, and hepatic steatosis the most 
predominant in our time.
One of the key mechanisms contributing to CLD progression is the continuous production and 
deposition of extracellular matrix (ECM) components such as collagen and glycoproteins, result-
ing in significant hepatic fibrosis and ultimately leading to the development of liver cirrhosis (or 
advanced CLD). Histologically cirrhosis is characterized by the formation of aberrant nodules and 
fibrotic septa in the parenchyma (Figure 1A) (2, 3).
Cirrhosis, as a dynamic process, can be clinically classified in different stages: (1) compensated 
cirrhosis without varices, (2) compensated cirrhosis with varices, (3) decompensated with ascites, 
and (4) decompensated with variceal bleeding. In the last stage, patients are more vulnerable to 
several complications such as infection, thrombosis, and development of hepatocellular carcinoma 
(3, 4). From a therapeutic point of view, different stages of the disease can also be considered as 
different “windows” for treatment; therefore, understanding the pathophysiology of CLD results 
essential to develop and apply effective treatments to patients with cirrhosis.
Portal hypertension (PH) is the most common and dreadful complication of CLD, and it occurs 
when the hepatic venous pressure gradient (HVPG) increases above 10 mmHg. Current therapies 
for PH aim to reduce HVPG below 12 mmHg (or 20% lower than basal pressure gradient) since 
FiGURe 1 | Major morphological characteristics of microvascular 
sinusoidal dysfunction in chronic liver disease (CLD). Continuous 
wound-healing processes in sinusoidal cells due to exogenous toxicants lead 
to marked changes in their phenotype. Exaggerated production and 
deposition of extracellular matrix, together with parenchymal extinction and 
vascular occlusion, lead to profound architectural distortion [as seen in panel 
(A): sirius red staining of control and cirrhotic human (top) and rat (bottom) 
livers, magnification 4×]. In addition, during CLD, liver sinusoidal endothelial 
cells become rapidly de-differentiated exhibiting marked reduction in their 
porosity, defined as fenestrae disappearance and basal membrane formation 
[panel (B): sinusoidal fenestrae analysis using scanning electron microscopy 
in livers from control and cirrhotic rats, magnification 15000×].
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it will markedly reduce the probability of decompensation and 
improve overall survival (5). The pathophysiology of PH defines 
the phenotypic alterations of all sinusoidal cells responsible for 
the hepatic vascular abnormalities that lead to the increment in 
portal pressure (6, 7). Indeed, the increase in the hepatic vascular 
resistance (HVR) due to both the architectural distortion, caused 
by deregulated fibrosis, and the microvascular dysfunction of 
sinusoidal cells is the primary factor in the development of PH 
(8–11). Secondary to HVR increment, mesenteric hypervolemia 
further contributes to aggravate and perpetuate the PH syndrome 
(12, 13).
Although CLD represents a very severe condition for humans, 
there are no available treatments to promote regression of liver 
fibrosis and the parallel amelioration of PH. In this sense, current 
research efforts mainly focus on developing effective therapeutic 
options to improve the phenotype of sinusoidal cells, which 
would lead to a global improvement of liver function.
SiNUSOiDAL CeLLS UNDeR THe CLD 
eNviRONMeNT
Non-parenchymal liver cells are well organized within the hepatic 
sinusoidal environment. They are indeed perfectly communi-
cated to each other to transmit different information related to 
physiological and pathophysiological conditions. Parenchymal 
cells are separated from liver sinusoidal cells by the space of 
Disse, where hepatic stellate cells (HSC) are located together 
with the components of ECM. The Kupffer cells (KC) reside in 
the sinusoid lumen. Liver cells are communicated with blood 
components through the specific fenestrae present in the liver 
endothelium, specifically in the cytoplasm of the liver sinusoidal 
endothelial cells (LSEC) (Figure 2).
During CLD progression, liver cells, and especially sinusoidal 
cells, try to adapt to this harmful environment changing their 
structure and function. These changes result in the alteration of 
vasodilatory, anti-inflammatory, and antioxidant programs that 
are essential for maintaining the healthy environment of the 
liver. Due to these alterations, liver sinusoidal cells switch from a 
protective phenotype to a pro-fibrotic one, favoring the develop-
ment of cirrhosis, its main complication PH, and ultimately liver 
failure (6, 8). The major adaptations and changes in sinusoidal 
cells phenotype are described below. Please note that the multiple 
deregulations and adaptations that parenchymal cells undergo 
during CLD, which also influence non-parenchymal cells pheno-
type, are intentionally omitted in the present review due to length 
restrictions.
Hepatic Stellate Cells
Hepatic stellate cells were described for the first time as star-
shaped cells by Carl von Kupffer in 1876, although these were 
renamed as fat-storing cells by Toshio Ito. Afterward, Kajiro Wake 
identified that HSC were loaded with vitamin-A fat droplets. The 
characteristic of storing lipids droplets allowed characterizing 
HSC as low-density perisinusoidal cells.
The main functions of quiescent HSC (qHSC) remain partly 
unidentified, being the storage and metabolism of retinoids a 
major one. qHSC also regulate the sinusoidal blood flow thanks 
to  their contractile capacity, although this function is more 
remarkable after their activation due to liver injury. In addition, 
qHSC produce several growth factors that are essential to modu-
late the function and proliferation of other hepatic cell types.
HSC Facing CLD: Activation
In response to liver injury, qHSC become “activated” (aHSC) 
toward an α-smooth muscle actin (α-SMA)-positive cell type 
characterized by enhanced contractility, increased migratory 
capacity, and high deposition of ECM components. In this regard, 
different molecular mechanisms are involved in HSC activation 
during CLD. These include the platelet-derived growth factor 
(PDGF)-α and -β receptors, the transforming growth factor 
β (TGFβ) signaling, and the Hedgehog (Hh) and canonical 
FiGURe 2 | Hepatic sinusoidal cells. In healthy livers, parenchymal and non-parenchymal hepatic cells are well organized and communicated to each other. 
Hepatic stellate cells (HSC) are situated into the space of Disse between hepatocytes and liver sinusoidal endothelial cells (LSEC). Liver resident macrophages, 
known as Kupffer cells (KC), are situated in the hepatic sinusoid lumen. Under normal conditions, hepatic cells present a functional structure: HSC store lipid 
droplets, hepatocytes possess microvilli indicating functionality, and the presence of fenestrae in LSEC allows the communication with other hepatic cells.
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Wnt/β-catenin signaling pathways among others. See below a 
summary of them.
In the initial phases of HSC transdifferentiation, PDGF-α 
and -β receptors are responsible for the modifications in their 
contractile and fibrogenic characteristics. PDGF receptors belong 
to the family of tyrosine kinase proteins that interact with their 
ligands to phosphorylate an internal tyrosine residue, activating 
several proliferation and migration signaling pathways, such 
as the Smad signaling cascade (14). It has been described that 
PDGF-α receptor promotes the TGFβ signaling in HSC through 
a Smad-dependent manner to ultimately induce differentiation 
of quiescent cells into myofibroblasts (15). As stated, TGFβ is one 
of the fibrogenic cytokines upregulated during the differentia-
tion of HSC through the activation of Smad proteins members 
(Figure 3). TGFβ binds to the constitutively active type II recep-
tor, which then recruits and phosphorylates the type I receptor. 
Smad2 and Smad3 proteins are phosphorylated by the interaction 
with type I receptor allowing the formation of a protein complex 
with Smad4. This complex is translocated into the nucleus where 
it regulates the transcription of target genes such as the colla-
gen family genes. On the contrary, Smad7 is a TGFβ signaling 
inhibitory protein that inhibits the phosphorylation of Smad2 
and Smad3 (12).
Moreover, TGFβ stimulates collagen transcription through a 
hydrogen peroxide (H2O2)- CCAAT-enhancer-binding proteins 
(C/EBPβ)-dependent mechanism (16, 17). Accordingly, oxidative 
stress plays a key role in HSC activation. Major sources of reac-
tive oxygen species (ROS) in HSC include NADPH oxidases and 
dysfunctional mitochondria (18).
Other transcriptional programs contributing to HSC activa-
tion include the canonical Hh and canonical Wnt/β-catenin 
signaling pathways.
Different studies described that Hh ligands regulate the 
activation of HSC promoting the transformation of qHSC to 
myofibroblasts, the accumulation of which contributes to CLD 
development (19, 20). As shown in Figure  4, in healthy livers, 
Hh ligands are absent or they are low expressed, and contrarily, 
the Hh-interacting protein (Hhip) is highly expressed disrupt-
ing the engagement between the Hh ligand and its receptor. 
However, when liver injury occurs, the production of Hh ligands 
increases, thus activating this signaling pathway. Particularly, it 
has been described that qHSC produce large amounts of Hhip, 
but upon activation, they produce Hh ligands through a PI3K/
AKT-dependent mechanism (21). The Hh ligands (Sonic Hh, 
Indian Hh, or Desert Hh) interact with the receptor Patched 
(Ptc) liberating the Smoothened (Smo) molecule. Smo inhibits 
the degradation of the Glioblastoma transcription factors (Gli) 
that are translocated to the nucleus influencing the expression 
of target genes that play key roles in the differentiation of HSC 
to myofibroblasts, and stimulating their proliferation and migra-
tion (22, 23). Gli1 and Gli2 generally increase gene transcription, 
while Gli3 can either increase or decrease gene transcription 
depending on its posttranslational modification (23, 24). Indeed, 
the transcription factor Gli2 is implicated in myofibroblast 
transformation by regulating the expression of Hh pathway 
components (Ptc, Hhip, and Gli1) as well as key activation genes 
including α-SMA and collagen type 1 (25, 26). On the other hand, 
the Hh pathway is also essential for the communication and the 
crosstalk between the HSC, the parenchymal, and sinusoidal cells 
through the formation of exosomes that contain functional Hh 
proteins (27).
The Wnt family proteins stimulate the β-catenin translocation 
to the nucleus to modulate different proliferation and pro-
inflammatory genes. Although there are some studies revealing 
that the activation of Wnt/β-catenin may maintain the quiescence 
of HSC (28, 29), growing literature supports the concept that 
activation of this signaling pathway contributes to HSC transdif-
ferentiation. Moreover, β-catenin interacts with Smad proteins in 
FiGURe 3 | TGFβ-Smad signaling pathway in HSC. The cytokine-transforming growth factor β (TGFβ) interacts with the active type II receptor (TGFβRII) 
permitting the phosphorylation of the type I receptor (TGFβRI). The proteins Smad2 and Smad3 are recruited for the TGFβRI where both are phosphorylated. This 
action allows the formation of the protein-complex Smad2, Smad3, and Smad4 that is translocated into the nucleus to regulate the transcription of target genes 
such as the collagen family genes. On the contrary, the protein Smad7 inhibits the Smad2 and Smad3 phosphorylation.
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the TGFβ pathway further promoting the transdifferentiation of 
HSC. Considering the controversial results regarding the Wnt/β-
catenin molecular pathway, further studies are needed to clarify 
its implication in the HSC activation process (30).
Liver Sinusoidal endothelial Cells
Liver sinusoidal endothelial cells (LSEC) are the very specialized 
and unique endothelial cells that compose the vascular sinusoidal 
walls in the liver. LSEC form a permeable barrier due to the pres-
ence of fenestrae in their cytoplasm and the lack of organized 
basement membrane. Prof. Eddie Wisse described LSEC in the 
70s using the electron microscopy technique.
It is important to denote that the peculiar discontinuous 
endothelium of the liver reduces the distance between the sinu-
soid and hepatocytes allowing their oxygenation and facilitating 
their exposition to molecules (<200 nm) from the portal circula-
tion. Liver sinusoids receive 30% of blood from the hepatic artery 
(highly oxygenated) and 70% from the portal vein (low oxygen). 
Therefore, fenestrae of the liver endothelium are indispensable 
for a proper oxygen supply to all hepatic cells.
Besides their sieve function, LSEC play a key role in the 
regulation of the hepatic vascular tone through the production 
of a variety of vasoactive molecules, probably being nitric oxide 
(NO) the most relevant one (31). In LSEC, NO is synthesized by 
the endothelial nitric oxide synthase (eNOS), which is transcrip-
tionally regulated by the transcription factor Kruppel-like factor 
2 (KLF2). In fact, KLF2 is highly expressed in the endothelium 
conferring vasoprotection by the induction of different vasodila-
tor and anti-inflammatory genes (32).
LSEC Facing CLD: Capillarization
In front of CLD, LSEC become profoundly deregulated, probably 
being the first hepatic cell type modifying its phenotype due to 
the external injury. The capillarization term refers to the loss of 
the specialized and unique phenotype of the LSEC in the liver. It 
occurs in response to liver damage, and LSEC lose their fenestrae 
(Figure  1B), develop basal membrane, and acquire vasocon-
strictor, pro-inflammatory, and pro-thrombotic properties (8). 
Indeed, and as stated above, in healthy livers, LSEC regulate 
hepatic vascular tone promoting the proper synthesis of vasoac-
tive molecules including vasodilators such as nitric oxide (NO), 
prostacyclin (PGI2) or carbon monoxide (CO), and vasocon-
strictors-like thromboxane A2 (TXA2), endothelin-1 (ET-1) or 
leukotrienes. However, upon chronic injury, LSEC exhibit a deep 
FiGURe 4 | Hedgehog signaling pathway. In healthy livers, the Hedgehog (Hh) pathway is inactivated in response to the low-expression of the Hh ligands (a), 
and to the inhibition of the Hh ligands and the receptor Patched (Ptc) interaction by the over-expressed Hh-interacting protein (Hhip) (b). Thus, the Glioblastoma (Gli) 
proteins are phosphorylated, ubiquitinated, and degraded (c). Under chronic liver disease environment, hepatic cells are able to secrete Hh ligands (d) that through 
the interaction with Ptc liberate the protein Smoothened (Smo) (e). Smo inhibits Gli degradation allowing its translocation into the nucleus where regulates target 
genes involved in the transdifferentiation of HSC and in the liver sinusoidal endothelial cell capillarization (f).
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imbalance favoring sinusoidal vasoconstriction, and, therefore, 
increasing the HVR (33, 34). Multiple mechanisms explain the 
imbalance in endothelial-derived vasoactive molecules. Briefly, 
elevated amounts of vasoconstrictors derived from increased 
expression of both intermediaries and key enzymes responsible 
for endothelin-1 or thromboxane production. In addition, low 
NO bioavailability is consequence of low eNOS activity and high 
NO-scavenging by the elevated oxidative stress present in the 
cirrhotic liver (35). Interestingly, it has been demonstrated that, 
in cirrhotic livers, KLF2 is upregulated in LSEC, which leads to 
increased eNOS mRNA expression, but not to elevated eNOS 
protein, thus suggesting a defect in its translation or degradation 
(32) (Figure 5).
It has been described that the Hh signaling pathway contrib-
utes to the capillarization of LSEC. The expression of Hh ligands 
(specifically SHh) and several Hh signaling components and 
target genes (Ptc receptor, Smo protein, and Gli2 and Gli3) are 
increased during capillarization of rat primary LSEC leading to 
the loss of fenestration (36) (Figure 3). Although LSEC produce 
Hh ligands, it remains unclear if the Hh-mediated loss in fenestrae 
is produced only by the direct action of the LSEC-Hh ligands 
that activate the Hh signaling cascade, or in addition by paracrine 
interactions from the Hh ligands produced by hepatocytes, HSC, 
cholangiocytes, and KC. In this sense, it has been shown that 
HSC release microparticles containing active forms of Hh ligands 
(SHh and IHh) that paracrinally induce changes in the expression 
of capillarization markers in LSEC (37).
On the contrary, vascular endothelial growth factor (VEGF) 
is necessary for the formation and maintenance of LSEC phe-
notype. Its expression depends on Hh signaling pathway and 
also on NO availability. Therefore, in cirrhosis, the activation of 
the Hh signaling pathway stimulates VEGF production, which 
will ultimately require autocrine production of NO by LSEC to 
preserve their fenestration (38, 39).
Kupffer Cells
The liver resident macrophages, known as KC, are situated into 
the sinusoidal lumen, which as stated above is composed of LSEC. 
KC represents the 80% of the total macrophages in the body and, 
in the liver, they are able to renew from resident stem cells. Since 
KC are exposed to blood as well as to antigens and bacterial endo-
toxins, they constitute the primary line of defense to maintain the 
FiGURe 5 | Kruppel-like factor 2 (KLF2) regulates nitric oxide (NO) bioavailability in liver sinusoidal endothelial cells. In healthy livers (black arrows), the 
transcription factor KLF2 regulates the endothelial nitric oxide synthase (eNOS) expression, which is responsible for NO synthesis, ultimately exerting its vasodilatory 
effects in the sinusoid. Under chronic liver disease environment (red arrows), and as compensatory mechanism, KLF2 is upregulated in the endothelium leading to 
increased eNOS mRNA expression, but not elevated eNOS protein. Moreover, elevated NO-scavenging by high levels of reactive oxygen species (specially, 
superoxide, O2
−) within the cirrhotic liver reduces even more NO bioavailability. Altogether, enhancing liver microvasculature constriction.
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immune system in the liver and to provide protection secreting 
anti-inflammatory molecules, such as interleukin-10 (IL-10) (40).
KC Facing CLD: Polarization
During CLD progression, inflammation has an important role 
modifying the phenotype of all sinusoidal cells, being KC major 
players in this pathological process. Find herein an outline of the 
inflammatory molecular mechanisms affecting/mediated by KC.
During liver injury, parenchymal cells undergo apoptosis, 
and/or necropotosis, secreting damage-associated-molecular-
patterns (DAMPs) that interact with KC through a toll-like 
receptor 4 (TLR4)-mediated mechanism. Importantly, in CLD, 
KC-TLR4 is also activated by pathogen-associated-molecular-
patterns (PAMPs) produced by the bacteria translocated from 
the gut to the liver, or by the gut-bacterial products reaching 
the liver due to gut leakiness (41). Regardless of the mechanism, 
TLR4 stimulation directly activates the canonical NFκB signaling 
pathway (42, 43) involving the phosphorylation of the subunit 
IκB by the NEMO-complex leading to the translocation of the 
p50–p65 NFκB dimer to the nucleus (Figure 6). In the nucleus, 
NFκB binds to RNA response elements to promote the transcrip-
tion of several pro-inflammatory cytokines (TNFα, IL-6, and 
TGFβ), chemokines, and reactive oxygen and nitrogen species. 
These pro-inflammatory molecules further contribute to global 
liver injury through paracrine communications. Indeed, they 
promote hepatocyte injury, deregulation of LSEC, and activation 
of HSC. Interestingly, it has also been reported that TNFα regu-
lates the apoptotic agents bcl-xL and p53, altogether promoting 
the survival of rat-activated HSC (33).
Chemokine family comprises a total of 70 proteins including 
chemokine ligands and chemokine receptors, and as stated above, 
are involved in the progression of liver fibrosis. The chemokine 
CCL2, also known as MCP-1, is an important chemokine 
implicated in the initiation of the inflammation process, in 
fibrogenesis, and in the development of NAFLD and NASH (44). 
It is secreted by KC, also by injured hepatocytes and activated 
HSC, with the subsequent accumulation of its receptor CCR2 in 
inflammatory monocytes. In fact, the CCL2–CCR2 complex is 
associated with the accumulation of macrophages within the liver 
altogether contributing to hepatic damage and HSC activation 
(45). Another well-characterized chemokine implicated in the 
progression of liver fibrosis is CCL5 or RANTES (46). Through 
the interaction with its CCR5 receptor, CCL5 is directly impli-
cated in the fibrogenic response mainly driven by HSC. On the 
contrary, the chemokine CX3CL1 exerts anti-inflammatory and 
antifibrogenic effects. Its receptor CX3CR1 represents a fibrosis 
resolution option mediating the restoration of macrophage phe-
notype by the inhibition of CCL2–CCR2 effects (47).
Finally, activated KC play also a prominent role regulating 
the hepatic vascular tone in CLD. Indeed, it has been dem-
onstrated that liver resident macrophages release substantial 
amounts of vasoconstrictor molecules, including TXA2 and 
cysteinyl-leukotrienes, that acting of neighboring HSC increase 
HVR (48, 49).
TAKiNG CARe OF SiNUSOiDAL CeLLS: 
NOveL TReATMeNTS FOR CLD AND PH
As described in the introduction, and although CLD and its 
complications represent a serious health problem in our society, 
there are not available treatments to promote cirrhosis regres-
sion. From studies using the new generation of antiviral drugs, 
FiGURe 6 | Toll-like receptor 4 (TLR4)-NFκB signaling pathway. The secretion of damage-associated-molecular-patterns (DAMPs) and pathogen-associated-
molecular-patterns (PAMPs) from injured hepatocytes and bacterial translocation due to chronic liver injury stimulates inflammatory processes through a TLR4-NFκB 
mechanism predominantly on Kupffer cells. TLR4 stimulation activates the canonical NFκB signaling pathway: the subunit IκB is phosphorylated by the NEMO-
complex liberating the p50–p65 NFκB dimer. Then, the NFκB dimer is translocated to the nucleus where it binds to RNA response elements to promote the 
transcription of pro-inflammatory cytokines, chemokines, reactive oxygen species, and reactive nitrogen species contributing to global liver injury.
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we now know that abrogation of the toxicant effector promotes 
some degree of spontaneous regression of fibrosis (50, 51), which 
can also be observed using preclinical models of cirrhosis (52). 
Nevertheless, additional efforts are required to find safe and reli-
able therapeutic options for patients with CLD and the associated 
clinical complications.
Considering the above exposed sinusoidal perspective, novel 
therapies to ameliorate CLD and its main complication (portal 
hypertension) should focus on improving the phenotype of all 
sinusoidal cells (53). Following this rationale, statins may rep-
resent a good option. Indeed, statins benefit both KC, HSC and 
LSEC. It has been described that statins, specifically simvastatin, 
are able to increase NO bioavailability in the sinusoidal compart-
ment by increasing the transcription factor KLF2, which induces 
the expression of eNOS and consequently increases the availability 
of this vasodilator, ultimately resulting in a decrease in the hepatic 
vascular tone. In addition, different studies have shown that 
statins promote the deactivation and apoptosis of activated HSC, 
thus reducing collagen synthesis and ameliorating sinusoidal 
vasoconstriction (54–58). Importantly, HSC improvement is 
also KLF2-RhoK-mediated. Moreover, and by a mechanism not 
totally understood, statins improve the phenotype of KC, which 
acquire an M2-type phenotype (58). In addition to the direct 
cellular effects of statins, we demonstrated that improvement of a 
specific sinusoidal cell type leads to concomitant improvement of 
neighboring cells through a paracrine mechanism (8).
Work from our team using aged animals suffering CLD (a 
preclinical model that closer resembles the clinical reality) rein-
forces the concept of global sinusoidal improvement in response 
to statins. Indeed, semi-chronic administration of simvastatin 
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promotes fibrosis regression and marked amelioration of PH (59), 
thus encouraging its use at the bedside. In this regard, different 
clinical trials and observational studies already proposed the ben-
efits of statins in patients suffering CLD (60–62). Although out of 
the scope of the present study, careful analysis of such excellent 
studies suggest that a specific “statins therapeutic window” may 
exist for patients with CLD. Future studies will hopefully clarify 
the appropriate use of these sinusoidal-protective drugs to pro-
mote regression of CLD.
Regarding the depleted NO bioavailability of cirrhotic livers, 
the use of antioxidants would be a good strategy to reduce oxida-
tive stress, particularly superoxide anion (O2−), which reacting with 
NO leads to the formation of peroxynitrite anion (ONOO−) and, 
therefore, results in reduced NO availability (63). Additionally, 
ROS directly react with eNOS inhibiting its phosphorylation 
and increasing its inhibitors (64). Previous studies tested several 
natural products with antioxidants properties such as vitamin 
C, flavonoids, and resveratrol in clinical and preclinical models 
(65–67), with mixed results in terms of improvement of CLD.
Additionally, several literature have defined different natural 
compounds, such as curcumin and tea polyphenols (EGCG and 
theaflavin), as inhibitors of the Wnt/β-catenin pathway result-
ing in HSC deactivation and amelioration of liver fibrosis (68), 
as well as regulating different cellular pathways implicated in 
liver carcinogenesis (69). New therapeutic strategies focused on 
the Wnt/β-catenin signaling pathway would be an interesting 
strategy to ameliorate hepatic fibrosis; however, this pathway also 
plays an important role in liver regeneration and hepatic zonation 
(70–72).
Several strategies aimed at improving inflammation and 
derived monocyte infiltration have been developed (45). It has 
been reported in preclinical models of fibrosis that inhibition 
of CCL2, or its receptor CCR2, promotes marked reduction in 
hepatic fibrosis (73). Additionally, the use of a CCL5 antagonist 
ameliorates liver fibrosis in mice (46). On the other hand, it 
is conceivable that the activation of CX3CL1 or the receptor 
CX3CR1 would be an alternative option to promote HSC deacti-
vation and regression of liver fibrosis (47). As mentioned before, 
these chemokines are regulated by the NFκB transcription factor. 
However, the effects of modulating this molecular pathway on 
hepatic fibrosis is not clear nowadays; under physiological condi-
tions, the activation of NFκB is essential to prevent hepatocytes 
apoptosis, being, therefore, protective, but an over-activation 
results in hepatic inflammation (74). Nevertheless, different 
preclinical studies have demonstrated that inhibition of NFκB 
accelerates the regression of hepatic fibrosis (42, 43). Similarly, 
the use of TLR4 antagonists represents an attractive option to 
ameliorate the inflammation processes occurring in the cirrhotic 
liver (41).
Many other therapeutic options are being characterized, both 
at benchside and bedside, with promising preliminary results. 
These include pan-caspase inhibitors (75, 76), GLP-1R and FXR 
agonists (77–79), and lysyl oxidase inhibitors (80). Upcoming 
results will clarify their usefulness and applicability in patients 
with CLD, nevertheless, their success will certainly rely on their 
capability to efficiently improve the phenotype of sinusoidal (and 
parenchymal) cells. Hopefully, future therapeutic developments 
will derive from synergistic efforts from basic researchers (with 
large knowledge on the biology of sinusoidal cells), clinicians 
(with deep experience in CLD pathophysiology), and private 
entities (aimed at improving patients health through supporting 
preclinical research). Concluding that the chances to succeed 
in the battle against CLD are directly proportional to the real 
improvement in the phenotype of hepatic cells considering the 
pathophysiology of the disease: the way to go on!
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